Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03479424 · ClinicalTrials.gov registry record
Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
A clinical trial, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- 30
- Enrollment target
NCT03479424: Clinical Trial study, sponsored by University of California, San Francisco.
NCT03479424 is a clinical trial that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03479424 was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The HOME PREDICT HF study looks at new ways to predict hospitalizations for heart failure. We will use a set of devices at home and surveys to collect information about patient's health. This study uses the Eureka app, a new study app developed by the University of California, San Francisco. The study is designed to happen remotely, using this application on a patient's smartphone, so that is as convenient as possible to participate.
Primary Outcome
Ninety-day heart failure hospitalization/emergency department visit for heart failure.
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-10-08 |
| Est. Completion | 2019-03-01 |
Why NCT03479424 stopped before completion
NCT03479424 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT03479424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03479424 about?
NCT03479424 is a clinical study titled "Home Outpatient Monitoring and Engagement to Predict HF Exacerbation". The HOME PREDICT HF study looks at new ways to predict hospitalizations for heart failure. We will use a set of devices at home and surveys to collect information about patient's health. This study uses the Eureka app, a new study app developed by the University of California, San Francisco. The stu...
What is the current status of trial NCT03479424?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2018-10-08. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT03479424?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT03479424?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI